Advaxis Biotech Immunotherapies for Cervical Cancer Trials Results On Board for 2012 As Additional Trial Enrollments Begin
Posted Jan 03 2012 1:39am
This is a recent video interview with the CEO of Advaxis giving an update on where they are with with their immunotherapies. As you can see they are going beyond breast and cervical cancer with neck and prostate cancer projects on the agenda.
The company was able to raise enough money this year to “feed the clinical trials machine” as he calls it to keep this important research alive and well. Biotech companies are struggling to catch all the funding they need at times and this is something we all need to be aware of. BD
Advaxis (ADXS: OTCBB) is a biotechnology company developing the next generation of immunotherapies for cancers and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to the bacteria to the cancer itself. SNNLive met with Tom Moore, CEO of Advaxis at the National Investment Banking Association Conference in Las Vegas 2011.